IP Library Granted Patent US 8,118,771
Granted Patent B2
US 8,118,771 · App. 11/926,608 · Granted Feb 21, 2012

Needleless injector drug capsule and a method for filling thereof

Assignee: Zogenix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,118,771
App. No.
11/926,608
Granted
Feb 21, 2012
Kind
B2
Abstract

A method for filling needleless injector capsules with liquid drug, whereby dissolved gas within the drug is replaced by a less soluble gas in order to reduce the inclusion of gas bubbles, or to prevent the growth of bubbles during storage and thereby prevent breakage of the capsules.

Claims (14)

1. A method of reducing breakage of a needle-free injector drug capsule, comprising:

preventing growth of bubbles in a liquid drug during storage by sparging the liquid drug with an inert gas having a solubility of 0.5 cm 3 to 25 cm 3 in 100 cm 3 of the liquid drug to obtain a sparged liquid drug;

loading the sparged liquid drug into a glass capsule strengthened with ion exchange; and

storing the capsule.

2. The method of claim 1 , wherein prior to loading the liquid drug into the capsule the capsule is evacuated to about 0.5 mbar.

3. The method as claimed in claim 1 , further comprising:

sealing the capsule in an atmosphere of the inert gas prior to loading the capsule.

4. The method as claimed in claim 1 , wherein the inert gas is selected from the group consisting of helium, argon, neon, krypton, xenon, nitrogen, a chlorofluorocarbon, a hydrofluorocarbon, and a mixture thereof.

5. The method as claimed in claim 1 , wherein the inert gas does not comprise helium.

6. The method as claimed in claim 1 , wherein the inert gas comprises helium.

7. The method as claimed in claim 1 , wherein the liquid drug is chosen from: a solution, and a suspension.

8. The method as claimed in claim 1 , further comprising:

forcing the inert gas through a filter comprising apertures of not more than 0.2 μm prior to contacting the gas with the liquid drug.

9. The method as claimed in claim 1 , wherein bubbles are prevented from growing above 2 μl in volume.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Aug 8, 2012
From: OXFORD FINANCE LLC, SUCCESSOR-IN-INTEREST TO OXFORD FINANCE CORPORATION
To: ZOGENIX, INC.
Reel/Frame 028752/0486 →
SECURITY AGREEMENT Recorded Jul 8, 2011
From: ZOGENIX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 026565/0778 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2008
From: ARADIGM CORPORATION
To: ZOGENIX, INC.
Reel/Frame 020482/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2008
From: HENRY, WILLIAM; LEWIS, ANDREW
To: ARADIGM CORPORATION
Reel/Frame 020485/0510 →
Priority Claims (1)
GB 0127942.1 · Nov 21, 2001 · national
Continuity (2)
Continuation 10496357
Related Publication 20080281260A1 · Nov 13, 2008